BMNDF
Price
$0.10
Change
-$0.00 (-0.00%)
Updated
Jun 25 closing price
Capitalization
7.75M
CLVLY
Price
$8.14
Change
+$0.19 (+2.39%)
Updated
Jul 30 closing price
Capitalization
419.35M
Interact to see
Advertisement

BMNDF vs CLVLY

Header iconBMNDF vs CLVLY Comparison
Open Charts BMNDF vs CLVLYBanner chart's image
BIOMIND LABS
Price$0.10
Change-$0.00 (-0.00%)
Volume$4.02K
Capitalization7.75M
Clinuvel Pharmaceuticals
Price$8.14
Change+$0.19 (+2.39%)
Volume$2.18K
Capitalization419.35M
BMNDF vs CLVLY Comparison Chart in %
Loading...
BMNDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLVLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMNDF vs. CLVLY commentary
Jul 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMNDF is a Buy and CLVLY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 31, 2025
Stock price -- (BMNDF: $0.10 vs. CLVLY: $8.14)
Brand notoriety: BMNDF and CLVLY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMNDF: 143% vs. CLVLY: 112%
Market capitalization -- BMNDF: $7.75M vs. CLVLY: $419.35M
BMNDF [@Biotechnology] is valued at $7.75M. CLVLY’s [@Biotechnology] market capitalization is $419.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $239.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMNDF’s FA Score shows that 0 FA rating(s) are green whileCLVLY’s FA Score has 1 green FA rating(s).

  • BMNDF’s FA Score: 0 green, 5 red.
  • CLVLY’s FA Score: 1 green, 4 red.
According to our system of comparison, CLVLY is a better buy in the long-term than BMNDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMNDF’s TA Score shows that 2 TA indicator(s) are bullish while CLVLY’s TA Score has 6 bullish TA indicator(s).

  • BMNDF’s TA Score: 2 bullish, 2 bearish.
  • CLVLY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CLVLY is a better buy in the short-term than BMNDF.

Price Growth

BMNDF (@Biotechnology) experienced а 0.00% price change this week, while CLVLY (@Biotechnology) price change was +6.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.29%. For the same industry, the average monthly price growth was +15.27%, and the average quarterly price growth was +40.33%.

Reported Earning Dates

CLVLY is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLVLY($419M) has a higher market cap than BMNDF($7.75M). CLVLY YTD gains are higher at: 5.714 vs. BMNDF (-67.490). CLVLY has higher annual earnings (EBITDA): 63.4M vs. BMNDF (-314.15K). CLVLY has higher revenues than BMNDF: CLVLY (91.6M) vs BMNDF (0).
BMNDFCLVLYBMNDF / CLVLY
Capitalization7.75M419M2%
EBITDA-314.15K63.4M-0%
Gain YTD-67.4905.714-1,181%
P/E RatioN/A16.30-
Revenue091.6M-
Total Cash10.1KN/A-
Total Debt883KN/A-
FUNDAMENTALS RATINGS
BMNDF vs CLVLY: Fundamental Ratings
BMNDF
CLVLY
OUTLOOK RATING
1..100
389
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
10045
PRICE GROWTH RATING
1..100
9649
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
6550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLVLY's Valuation (4) in the null industry is significantly better than the same rating for BMNDF (96). This means that CLVLY’s stock grew significantly faster than BMNDF’s over the last 12 months.

BMNDF's Profit vs Risk Rating (93) in the null industry is in the same range as CLVLY (100). This means that BMNDF’s stock grew similarly to CLVLY’s over the last 12 months.

CLVLY's SMR Rating (45) in the null industry is somewhat better than the same rating for BMNDF (100). This means that CLVLY’s stock grew somewhat faster than BMNDF’s over the last 12 months.

CLVLY's Price Growth Rating (49) in the null industry is somewhat better than the same rating for BMNDF (96). This means that CLVLY’s stock grew somewhat faster than BMNDF’s over the last 12 months.

CLVLY's P/E Growth Rating (90) in the null industry is in the same range as BMNDF (100). This means that CLVLY’s stock grew similarly to BMNDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMNDFCLVLY
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
54%
MACD
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
42%
Bullish Trend 1 day ago
62%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
41%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
N/A
Bullish Trend 1 day ago
58%
Declines
ODDS (%)
N/A
Bearish Trend 7 days ago
76%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
14%
Bullish Trend 1 day ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
BMNDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLVLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ATEYX168.97N/A
N/A
AB Sustainable Global Thematic Advisor
WAMFX24.03N/A
N/A
Boston Trust Walden Midcap
JEPAX14.14N/A
N/A
JPMorgan Equity Premium Income A
SEVIX14.74N/A
N/A
SEI US Managed Volatility I (SIMT)
EEIFX9.90N/A
N/A
Monteagle Enhanced Equity Income Instl

BMNDF and

Correlation & Price change

A.I.dvisor tells us that BMNDF and APM have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMNDF and APM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMNDF
1D Price
Change %
BMNDF100%
N/A
APM - BMNDF
27%
Poorly correlated
+1.84%
LVTX - BMNDF
23%
Poorly correlated
-3.40%
PHGE - BMNDF
22%
Poorly correlated
-1.21%
CYDY - BMNDF
12%
Poorly correlated
+4.60%
CLVLY - BMNDF
1%
Poorly correlated
+2.39%
More

CLVLY and

Correlation & Price change

A.I.dvisor tells us that CLVLY and ADAP have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLVLY and ADAP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLVLY
1D Price
Change %
CLVLY100%
+2.39%
ADAP - CLVLY
22%
Poorly correlated
-5.05%
QLGN - CLVLY
21%
Poorly correlated
-0.20%
ATNM - CLVLY
20%
Poorly correlated
-2.48%
BSEM - CLVLY
11%
Poorly correlated
+1.41%
CMXHF - CLVLY
10%
Poorly correlated
+0.27%
More